Predict your next investment

Epitomee Medical company logo
HEALTHCARE | Medical Devices & Equipment / Therapeutic Devices
epitomeemedical.com

See what CB Insights has to offer

Founded Year

2005

Stage

Unattributed VC | Alive

Total Raised

$8M

Last Raised

$8M | 3 yrs ago

About Epitomee Medical

Epitomee Medical is a private company developing and commercializing drug-free self-administered, shapeshifting capsules, aimed to prevent diabetes and address overweight & obesity co-morbidities by promoting weight loss and establishing a healthier lifestyle.

Epitomee Medical Headquarter Location

Tarshish Industrial Park St

Caesarea, 3079563,

Israel

+972 (72)-2505995

Latest Epitomee Medical News

Now Recruiting Patients for a New FDA Oversight Trial Evaluating the Use of a Patient's Own Fat Tissue for the Treatment of Post-COVID-19 Lung Damage

Nov 17, 2020

Promising research leads to formal trial sponsored and funded by Tulip Medical. (tulipmedical.com) Download Alveolus in COVID-19 losing gas exchange capability (Graphic: Business Wire) November 17, 2020 06:00 AM Eastern Standard Time SAN DIEGO--( BUSINESS WIRE )-- Tulip Medical (a dba of Black Tie Medical, Inc.) has sponsored and funded a new FDA Oversight Trial that seeks to restore respiratory function in adults who have suffered lung damage from the COVID-19 virus. Robert W. Alexander, MD, DMD, FICS is the Principal Investigator, and his office is recruiting patients for enrollment in the trial. "We're building on two years of existing trials in patients suffering from Chronic Obstructive Pulmonary Disease (COPD) and Farmer's Lung Disease (FLD)," says Dr. Robert W. Alexander, MD, DMD, FICS. "The existing clinical trials in lung disease using the body's own adult stem/stromal cells derived from fat have shown promising improvements as it relates to the gas exchange function that happens in healthy lungs. This is one of the common long-term effects on people who have contracted Coronavirus," explained Alexander. "The sterile, coated closed syringe microcannula systems and adipose processing solutions invented by Tulip Medical, San Diego, CA, USA, (the sponsor of the study) have proven to be among the most reliable and trusted systems available for the gentle, safe and easy access to these adipose cells and attachment media (ECM)," says Dr. Alexander. "It is truly a pleasure to sponsor and fund this critical trial developed by Dr. Alexander," says Marcille Pilkington, Co-founder, President, and CEO of Tulip Medical. "Dr. Alexander's work thus far treating COPD and FLD patients who have run out of options is inspiring. Many of these patients, who have been told to get their affairs in order, experience improved lung function and quality of life after treatment. Logically, a similar protocol might be effective with lung damage in recovering COVID patients." More information about the protocols and merits of the study, as well as the research that has led to the FDA's oversight of a patient trial, is available on the San Diego Academy of Regenerative Therapies ( SDARTS.com ) Online Learning Platform . The Panel discussion recorded on October 1, 2020, features Dr. Alexander and Dr. Ramon Llull, MD, Ph.D ., a research colleague who has done extensive studies on the use of cellular Stromal Vascular Fraction (cSVF). "Fat contains cells with the intrinsic capacity of healing: the strength to mend scaffolds, bleeding vessels, and extinguish inflammation within the tissues," says Dr. Llull. "This will be of critical benefit for COVID-19 patients who have experienced scarring in the lungs. Based on our research, we are fairly confident that these therapies might be the answer to achieving compliant, healthy lungs." Tulip Medical is a subsidiary of SDARTs. Patients considering participation in this clinical trial should email Dr. Alexander at irbtrials@gmail.com .

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Epitomee Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Epitomee Medical is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

7,889 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

D

Diabetes

1,750 items

Epitomee Medical Patents

Epitomee Medical has filed 9 patents.

The 3 most popular patent topics include:

  • Acetylcholinesterase inhibitors
  • Androstanes
  • Aromatase inhibitors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/4/2014

9/28/2021

Dosage forms, Drug delivery devices, Digestive system, Pharmacokinetics, Routes of administration

Grant

Application Date

12/4/2014

Grant Date

9/28/2021

Title

Related Topics

Dosage forms, Drug delivery devices, Digestive system, Pharmacokinetics, Routes of administration

Status

Grant

Epitomee Medical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Epitomee Medical Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.